Treatment of ocular inflammatory conditions with loteprednol etabonate

British Journal of Ophthalmology

Volumn 92, Issue 4, 2008, Pages 455-459

  Pavesio, C E ^a   DeCory, H H ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; DRUG METABOLITE; IMMUNOMODULATING AGENT; LOTEPREDNOL ETABONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISOLONE ACETATE; STEROID;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRY EYE; ESTERIFICATION; EYE INFLAMMATION; GIANT PAPILLARY CONJUNCTIVITIS; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LACRIMAL GLAND DISEASE; MEDIATOR RELEASE; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UVEITIS;

ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; CONJUNCTIVITIS; CONJUNCTIVITIS, ALLERGIC; DRY EYE SYNDROMES; ENDOPHTHALMITIS; HUMANS; POSTOPERATIVE COMPLICATIONS; UVEITIS, ANTERIOR;

EID: 41849140855     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.132621     Document Type: Review

References (57)

1. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 1999;18:357-70.
2. Allansmith MR, Korb DR, Greiner JV, et al. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 1977;83:697-708.
3. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986;30:229-44.
4. Donshik P. Contact lens chemistry and giant papillary conjunctivitis. Eye Contact Lens 2003;29:37-9S.
5. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18:485-92.
6. Samudre SS, Lattanzio FA Jr, Williams PB, et al. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 2004;20:533-47.
7. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42.
8. Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg 1998;24:1480-9.
9. Janeway C, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease. New York: Garland Science Publishing, Taylor & Francis, 2005:12-13.
10. Bhargava A, Jackson WB, El-Defrawy SR. Ocular allergic disease. Drugs Today (Barc) 1998;34:957-71.
11. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500.
12. Becker MD, Smith JR, Max R, et al. Management of sight-threatening uveitis: new therapeutic options. Drugs 2005;65:497-519.
13. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218:223-36.
14. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-53.
15. Siddique M, Manzouri B, Flynn TH, et al. Allergy and contact lenses. Chem Immunol Allergy 2007;92:166-75.
16. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999;127:537-44.
17. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997;123:455-64.
18. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
19. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30:10-13.
20. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-83.
21. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003;16:321-5.
22. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-7.
23. Bodor N, Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res 1992;11:525-30.
24. Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984;4:449-69.
25. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58-101.
26. Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984;74:1803-10.
27. Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-65.
28. Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998;105:1780-6.
29. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997;23:31-6.
30. Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:313-21.
31. Dell SJ, Lowry GM, Northcutt JA, et al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998;102:251-5.
32. Dell SJ, Shulman DG, Lowry GM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997;123:791-7.
33. Grigorian R, Shah A, Guo S. Comparison of loteprednol etabonate 0.5% (Lotemax) to prednisolone acetate 1% (Falcon) for inflammation treatment following cataract surgery. 2007 ARVO Annual Meeting: The Aging Eye; 6 May 2007, Fort Lauderdale, FL. Poster B1040, 2007.
34. Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50-5.
35. Bielory L. Allergic diseases of the eye. Med Clin North Am 2006;90:129-48.
36. Donshik P. Giant papillary conjunctivitis. Trans Am Ophthalmol Soc 1994;92:687-744.
37. Spring TF. Beaction to hydrophilic lenses. Med J Aust 1974;1:449-50.
38. Chambless SL, Trocme S. Developments in ocular allergy. Curr Opin Allergy Clin Immunol 2004;4:431-4.
39. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999;106:362-9.
40. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996;121:35-46.
41. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 2000;55:178-83.
42. Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf 2007;5:75-92.
43. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61.
44. Blehm C, Vishnu S, Khattak A, et al. Computer vision syndrome: a review. Surv Ophthalmol 2005;50:253-62.
45. Bielory L. Ocular allergy and dry eye syndrome. Curr Opin Allergy Clin Immunol 2004;4:421-4.
46. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol 2001;45(2 Suppl):199-202S.
47. O'Brien PD, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 2004;4:314-9.
48. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25:900-7.
49. Pflugfelder SC, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf 2007;5:163-78.
50. Holland EJ, Donnenfeld ED, Lindstrom RL, et al. Expert consensus in the treatment of dry eye inflammation. Ophthalmol Times 2007;32:1-12.
51. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138:444-57.
52. El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2001;12:4-8.
53. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000;11:3-6.
54. American Academy of Ophthalmology. Cataract in the adult eye, preferred practice pattern. San Francisco: American Academy of Ophthalmology, 2006:30-2.
55. Schmier J, Halpern M, Covert D, et al. Evaluation of Medicare costs of endophthalmitis among patients after cataract surgery. Ophthalmology 2007;114:1094-9.
56. Callegan MC, Engelbert M, Parke DW 2nd, et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev 2002;15:111-24.
57. Holland EJ. Attenuation of ocular hypertension in steroid responders following corneal transplantation with the use of topical 0.5% loteprednol etabonate. Refr Eyecare Ophthalmol 2004;8:4S.